Effects of Anti-Tuberculosis Drugs on Lipid Profile in Pulmonary Tuberculosis Patients

Abstract

Objective: To determine the anti-tuberculosis drugs effect on the lipid profile parameters in pulmonary tuberculosis (TB) patients. Methods: A prospective cross-sectional study was conducted at Tehsil Headquarter Hospital, Taunsa Sharif and District Headquarter Teaching Hospital, Dera Ghazi Khan from December 2020 to May 2021. The blood samples from 84 positive pulmonary TB patients were collected in three different intervals of the study, before the start of the treatment, and after the use of first four baseline drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) respectively to check out the variation in lipid profile parameters such as total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and very low density lipoprotein (VLDL). Results: Of 84 pulmonary TB patients, the mean age was 38.1 ± 19.8 years. There were 44 (52.4%) males and 40 th th (47.6%) females. The mean difference of cholesterol level significantly increases from baseline to 6 and 10 week, (p-value <0.001). Similarly, HDL (p-value <0.001) and LDL (p-value <0.001) also increases significantly from th th baseline to 6 week and 10 week. However, no significant difference of TG (p-value 0.908) and VLDL (p-value th th 0.367) was observed from baseline to 6 and 10 week. Conclusion: Patients with pulmonary TB showed low lipid profile in our cohort. This shows that pulmonary TB may be a causative agent of low lipid profile. After anti-TB therapy, cholesterol, HDL, and LDL levels seem to be increased.